Reports the comparative efficacy and safety of cetuximab versus methotrexate in frail older patients, suggesting a potential first-line treatment option.
At present, there is no established standard treatment for frail older patients with recurrent or metastatic head and neck squamous cell carcinoma. We aimed to compare the efficacy and safety of cetuximab to those of methotrexate (the reference regimen) in this population.
No takes yet. Share an insight, caveat, or question.
Guigay et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: